Oppenheimer Assumes Evaxion Biotech at Outperform, Announces Price Target of $16

Benzinga Real-time News ·  Jul 18, 2022 10:34

Oppenheimer analyst Jeff Jones assumes Evaxion Biotech (NASDAQ:EVAX) with a Outperform rating and announces Price Target of $16.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment